Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in areas outside the U.S. where the medication is not available. The companies have created a global named patient program, also known as an early or expanded access program, which provides physicians with a framework to legally and ethically prescribe investigational or approved drugs for patients before they become commercially available. Under the agreement, Tanner will be the exclusive supplier of…
You must be logged in to read/download the full post.
The post Partnership Improves Patient Access to Apealea Outside US appeared first on BioNewsFeeds.